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Background: To determine whether renal perfusion with cold crystalloid solution enriched with histidine-tryptophan-
ketoglutarate (Custodiol; Dr Franz-Kohler Chemie GmbH, Bensheim, Germany) provides better protection against renal
ischemic injury than cold lactated Ringer’s solution in patients undergoing thoracoabdominal aortic aneurysm open repair.
Methods: We analyzed a prospectively compiled database containing all 111 consecutive patients who underwent thor-
acoabdominal aortic aneurysm open repair at our center from 2008 to 2011. A cohort of 104 consecutive patients was
identiﬁed of which 50 (48%) had renal perfusion with Custodiol and 54 (52%) with lactated Ringer’s solution. Propensity
score matching based on baseline clinical variables, which were expected to inﬂuence renal outcomes, was performed to
correct for any bias that may have been associated with the use of Custodiol. Acute kidney injury (AKI) as deﬁned by
Kidney Disease Improving Global Outcomes guidelines and perioperative estimated glomerular ﬁltration rate were
compared in the two groups. Independent predictors of AKI were also identiﬁed by multivariate analysis.
Results: After propensity scorematching,wewere able tomatch42Custodiol casesone-to-onewith those receivingperfusion
with lactated Ringer’s solution. Overall 30-day mortality was 5.9%; temporary hemodialysis or continuous veno-venous
hemoﬁltration was needed in 4.8% of the patients without any case of dialysis at discharge. Freedom from AKI was signif-
icantly increased in the Custodiol group (38.1% vs 9.5%; P [ .002) despite longer total renal ischemic time (51.5 6
16.4minutes vs 43.66 16.0minutes; P[ .05). By analysis of variance for repeatedmeasures, a signiﬁcant upward trend of
perioperative estimated glomerular ﬁltration rate was observed in the Custodiol group (group3 time interaction[ F3,66;
P < .001), and by multivariate analysis, Custodiol perfusion was the only independent predictor of non-AKI (P[ .04).
Conclusions: The use of Custodiol was safe and provided improved perioperative renal function compared with lactated
Ringer’s solution. Randomized trials are needed to conﬁrm these data and to assess their clinical consequences. (J Vasc
Surg 2014;59:623-33.)Contemporary open thoracoabdominal aortic aneu-
rysm (TAAA) repair is characterized by respectable early
outcomes, particularly when repair is elective. This has
mostly been due to the use of a multimodal approach
guided by the TAAA Crawford’s extent and based on
moderate systemic heparinization, permissive mild hypo-
thermia, and multiple adjuncts against ischemic organ
damage such as left heart bypass (LHBP) and cerebrospinal
ﬂuid (CSF) drainage.1
Recent consensus practice guidelines recommend
either cold crystalloid or blood perfusion to be considered
for renal protection during TAAA repair (class IIb, level of
evidence B).2 As the most studied crystalloid solution is
lactated Ringer’s solution,3,4 this kind of renal perfusion
can be considered as a benchmark for the evaluation of
the efﬁcacy of other substrates.the Vascular Surgerya and Anesthesia and Intensive Care,b Università
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://dx.doi.org/10.1016/j.jvs.2013.09.055Histidine-tryptophan-ketoglutarate (Custodiol; Dr
Franz-Kohler Chemie GmbH, Bensheim, Germany) solu-
tion is an enriched crystalloid solution approved by the
U.S. Food and Drug Administration as a medical device
for the preservation of several organs in nonheart-beating
donor transplantation as well as for cardioplegia in open
heart surgical procedures. An evaluation of renal perfusion
with Custodiol during TAAA open repair together with
a comparison with other crystalloids has never been carried
out, to the best of our knowledge. The purpose of this
study is to assess the effectiveness in renal protection of
Custodiol in this novel clinical setting compared with renal
perfusion with lactated Ringer’s solution.
METHODS
We analyzed a prospectively compiled single-center
database containing all TAAA open repairs performed in
our center from 2008 to 2011. Since 2009, our standard
protocol of renal perfusion with 4C lactated Ringer’s solu-
tion implemented with mannitol and methylprednisolone
has changed, shifting to the use of 4C Custodiol. The
main components, osmolality and pH at 4C of both
lactated Ringer’s solution and Custodiol are reported and
compared in Table I.
Primary end points of the study were the following: (1)
to assess whether postoperative acute kidney injury (AKI),
as deﬁned by the Kidney Disease Improving Global
Outcomes clinical practice guidelines (Table II),5-9 are623
Table I. Main characteristics of lactated Ringer’s
solution and Custodiol solution
Ringer’s lactate
solution,
mmol/L
Custodiol
solution,
mmol/L
Sodium chloride 130.0 15.0
Potassium chloride 4.0 9.0
Magnesium chloride $ 6 H2O 0.0 4.0
Histidine hydrochloride $ H2O 0.0 18.0
Histidine 0.0 180.0
Tryptophan 0.0 2.0
Mannitol 96.4a 30.0
Calcium chloride $ 2 H2O 2.7 0.015
Sodium lactate 28.0 0.0
Potassium hydrogen
2-ketoglutarate
0.0 1.0
Methylprednisolone 125 mg/La 0
Osmolality 281 mOsm/La 310 mOsm/L
pH (at 4C) 6.21a 7.4-7.45
aIn the present study, renal perfusion with lactated Ringer’s solution was
implemented with mannitol (96.4 mmol/L) and with methylprednisolone
(125 mg/L). We measured osmolality and pH (at 4C) of the modiﬁed
solution, and we observed only slight changes in pH and osmolality
compared with the original lactated Ringer’s solution. In particular, pH
changed from 6.21 to 6.24 (OM-6050 OSMO STATIONTM; A. Menarini
Diagnostics, Florence, Italy) and the osmolality from 278 mOsm/L to 281
mOsm/L (MP220 Basic pH/mV/C Meter e METTLER TOLEDO;
Novate Milanese, Milan, Italy). In this table, the values of the modiﬁed
solution are reported. Custodiol solution was administered without any
implementation.
Table II. Diagnostic criteria for acute kidney injury
(AKI) according to the Risk, Injury, Failure, Loss, and
End-stage kidney disease (RIFLE) nomenclature and
classiﬁcation41,42
AKI
stage Serum creatinine criteria
Urine output
criteria
1 1.5-1.9 times or $ 0.3 mg/dL
($26.5 mmol/L) increase within
48 hours
<0.5 mL/kg/h for
6-12 hours
2 2.0-2.9 times baseline <0.5 mL/kg/h for
$12 hours
3 3.0 times baseline or increase in
serum creatinine $ 4.0 mg/dL
($353.6 mmol/L) or initiation of
renal replacement therapy or in
patients <18 years a decrease in
eGFR to<35 mL/min per 1.73 m2
<0.3 mL/kg/h for
$24 hours or
anuria for
$12 hours
eGFR, Estimated glomerular ﬁltration rate.
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diol renal perfusion compared with standard Ringer’s
perfusion; (2) to compare perioperative trend (from preop-
erative value up to postoperative day 6 value) of estimated
glomerular ﬁltration rate (eGFR), calculated on a daily
basis by using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) formula10-12 between the two
renal perfusion groups; and (3) to identify independent
predictors of postoperative AKI.
Serum creatinine was measured daily throughout the
study period with the same enzymatic method (kinetic
method with alkaline picrate) and the same biochemical
analyzer (Advia 2400 Chemistry System WKC/MET085;
Siemens Healthcare Diagnostics, Erlangen, Germany).
Glomerular ﬁltration rate, expressed as mL/min/
1.73 m2, was calculated on a daily basis by using the
CKD-EPI formula.10-12
To determine the study sample size for the evaluation
of whether Custodiol renal perfusion may reduce postoper-
ative AKI, a power analysis was performed that was based
on two assumptions: (1) 87% of patients in the Custodiol
group would develop AKI, as derived from perioperative
AKI rate in patients who had undergone TAAA repair in
our Center over the last 2 years having had renal perfusion
with lactated Ringer’s solution; and (2) if effective, the
renal perfusion with Custodiol would reduce the rate of
AKI by two-thirds. From these assumptions, we deter-
mined that 38 patients would be needed in each group
to achieve 80% power with a ¼ .05.The study included all consecutive adult patients who
had renal cold crystalloid perfusion during elective TAAA
open repair without the need for hypothermic circulatory
arrest. A total of 111 consecutive adult patients who under-
went elective TAAA open repair were collected. One
hundred four patients who had had renal cold crystalloid
perfusion were included in the analysis. During the study
period, seven patients were excluded from the analysis
having had surgery without crystalloid renal perfusion for
the TAAA Crawford’s extent not involving renal arteries
(three TAAA extent I), for intraoperative technical concerns
(three cases), and for intentional choice of the surgeon to
perform an isothermic renal blood perfusion (one case).
All patients matching inclusion criteria were Caucasian
and were divided into two groups according to the renal
perfusion solution that had been used: (1) Ringer’s group
(April 2008-August 2009, 54 patients): the last consecu-
tive TAAA open repairs undergoing renal perfusion with
4C lactated Ringer’s solution from April 2008; and (2)
Custodiol group (September 2009-December 2011, 50
patients): the ﬁrst consecutive TAAA open repairs under-
going renal perfusion with 4C Custodiol solution from
September 2009. For inclusion in this group, approval
from our Institutional Review Board and a speciﬁc written
informed consent from all patients were obtained.
A propensity score adjustment based on preopera-
tive clinical variables, which were expected to inﬂuence
renal outcomes was performed to correct for any bias
that may have been associated with the renal perfusion
with Custodiol.13-15
Every patient was then followed for at least 1 year in the
outpatient clinic at 3, 6, and 12months, and then annually if
not otherwise required, to evaluate dialysis-free survival.
Surgical technique. Surgical technique and adjuncts
of organ protection were mainly guided according to
TAAACrawford extent as reported in Tables III and IV.16,17
A double-lumen endotracheal tube was used in all the
patients positioned in a right lateral decubitus over
Table III. Preoperative clinical characteristics of 84 propensity score-matched patients who underwent repair of
thoracoabdominal aortic aneurysm (TAAA)
Total (n ¼ 84) Ringer’s group (n ¼ 42) Custodiol group (n ¼ 42) P value
Sex
Male 65 (77.4) 33 (78.6) 32 (76.2) .79
Female 19 (22.6) 9 (21.4) 10 (23.8) .79
Age, years 66.5 6 8.27 66.5 6 5.60 66.5 6 10.35 .98
Age, $65 years 56 (66.7) 27 (64.3) 29 (69.0) .81
Classiﬁcation of aneurysms
TAAA extent I 0 (0) 0 (0) 0 (0) .99
TAAA extent II 25 (29.8) 10 (23.8) 15 (35.7) .34
TAAA extent III 32 (38.1) 19 (45.2) 13 (30.9) .26
TAAA extent IV 27 (32.1) 13 (30.9) 14 (33.3) .99
TAAA extent V 0 (0) 0 (0) 0 (0) .99
Aneurysm
Maximum aortic diameter, mm 65.6 6 15.20 66.4 6 16.98 64.8 6 13.34 .64
Quartile 1 (<55 mm) 14 (16.7) 8 (19.0) 6 (14.3) .77
Quartile 2 (55-60 mm) 22 (26.2) 10 (23.8) 12 (28.6) .80
Quartile 3 (61-69 mm) 24 (28.6) 12 (28.6) 12 (28.6) .99
Quartile 4 (>70 mm) 24 (28.6) 12 (28.6) 12 (28.6) .99
Chronic dissection 6 (7.1) 3 (7.1) 3 (7.1) .99
Connettive tissue disease 2 (2.4) 0 (0) 2 (4.7) .15
Symptoms 19 (22.6) 12 (28.6) 7 (16.7) .29
Principal comorbidities
Hypertension 77 (91.7) 38 (90.5) 39 (92.9) .69
Diabetes mellitus 18 (21.4) 10 (23.8) 8 (19.0) .79
Dyslipidemia 46 (54.8) 23 (54.8) 23 (54.8) .99
Active smoking 32 (38.1) 21 (50.0) 11 (26.2) .05
History of smoking 78 (92.8) 38 (90.5) 40 (95.2) .67
COPD 60 (71.4) 29 (69.0) 31 (73.8) .81
Extracardiac arteriopathy 35 (41.7) 16 (38.1) 19 (45.2) .65
Coronary artery disease 28 (33.3) 16 (38.1) 12 (28.6) .48
Cerebrovascular disease 5 (5.9) 3 (7.1) 2 (4.7) .99
Dialysis 0 (0) 0 (0) 0 (0) .99
CKD stages
Stage I 25 (29.8) 12 (28.6) 13 (30.9) .81
Stage II 35 (41.7) 19 (45.2) 16 (38.1) .51
Stage III 20 (23.8) 9 (21.4) 11 (26.2) .60
Stage IV 4 (4.7) 2 (4.8) 2 (4.8) .99
Stage V 0 (0) 0 (0) 0 (0) .99
ASA score 3.4 6 0.51 3.3 6 0.52 3.4 6 0.50 .21
ASA, American Society of Anesthesiologists; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; SD, standard deviation.
Data are presented at number (%) and mean 6 standard deviation.
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Crawford extent II and III and in selected cases in extent
IV. CSF pressure monitoring was usually maintained
during the ﬁrst 48 to 72 hours between 8 and 10 mm
Hg using an automatic system (LiquoGuard; Möller
Medical GmbH & Co KG, Fulda, Germany) simulta-
neously allowing CSF pressure measurements and CSF
drainage through a closed system with dual pressure
sensors with an electronically controlled peristaltic pump.
We typically approached the TAAA Crawford extent II
through a thoraco-phreno-laparotomy in the ﬁfth inter-
costal space and the extent III and IV in the seventh or
eighth. An LHBP including an inline centrifugal pump
without a cardiotomy reservoir, or an oxygenator was used
for distal aortic perfusion routinely in TAAA extent II and
III and selectively in extent IV (Table IV). The cannula
for the outﬂow from the patient was located in the left supe-
rior pulmonary vein (usually a 20F moldable cannula) or in
the descending aorta (usually a 16-18F standard cannula).The cannula for the inﬂow (usually a percutaneous 14F
cannula allowing ipsilateral lower limb perfusion during
LHBP) was located through an over-the-wire technique
(.03500) in the left common femoral artery. A systemic hepa-
rinization was always performed to obtain an activated clot-
ting time of >200 seconds. The circuit was primed with
400 mL of lactated Ringer’s solution, or in the case of
anemia, with the patient’s autologous blood. The LHBP
was started at a ﬂow ranging between 1500 and 2500 mL/
min to maintain a distal arterial pressure of 70 mm Hg.
Mild hypothermia (34C-35C) was routinely allowed.
Whenever possible, sequential clamping was per-
formed; the aorta was then opened between the clamps
and back-bleeding from intercostal arteries was temporary
stopped with 3 or 4F occlusion balloon catheters (Pruitt;
Lemaitre Vascular, Inc Burlington, Mass). A woven
Dacron graft was usually used and sutured end-to-end to
the proximal aortic neck. The distal clamp was moved to
the supraceliac aorta, all descending aorta was opened,
Table IV. Intraoperative surgical details of 84 propensity score-matched patients who underwent repair of
thoracoabdominal aortic aneurysm (TAAA)
Total (n ¼ 84) Ringer’s group (n ¼ 42) Custodiol group (n ¼ 42) P value
CSF drainage 65 (77.4) 32 (76.2) 33 (78.6) .99
LHBP 59 (70.2) 28 (66.6) 31 (73.8) .63
Renal perfusion 84 (100) 42 (100) 42 (100) .99
Celiac/SMA perfusion 84 (100) 42 (100) 42 (100) .99
Carrel patch on visceral arteries 58 (69.0) 26 (61.9) 32 (76.2) .24
Selective reimplantation of left renal artery 39 (46.4) 19 (45.2) 20 (47.6) .99
Selective reimplantation of polar artery 6 (7.3) 4 (9.5) 2 (5.0) .43
Operative repair time, minutes 275.3 6 70.58 263.2 6 65.05 287.6 6 74.49 .11
Clamping time, minutes 47.0 6 18.72 44.3 6 18.09 49.7 6 19.17 .19
Visceral perfusion time, minutes 22.6 6 11.42 20.7 6 13.01 24.4 6 9.60 .17
Intercostal/lumbar artery reimplantation 19 (22.6) 11 (26.2) 8 (19.0) .60
Renal stenting 12 (14.3) 1 (2.4) 11 (26.2) .002
Renal endoarterectomy 9 (10.7) 8 (19.0) 1 (2.4) .01
Total renal perfusion volume, mL 826 6 264 850 6 250 803 6 278 .37
Total visceral ischemic time, minutes 47.1 6 20.35 43.4 6 19.48 50.5 6 20.77 .11
Total renal ischemic time, minutes 47.9 6 16.61 43.6 6 15.99 51.5 6 16.48 .053
Isothermic renal distal perfusion time, minutes 24.3 6 13.20 21.4 6 12.62 26.9 6 13.34 .09
Cold renal perfusion time, minutes 24.0 6 11.01 22.4 6 12.27 25.5 6 9.70 .24
Urine output during operation, mL 1435.0 6 763.31 1378.1 6 726.8 1492.0 6 802.84 .49
Intraoperative losses 4326.7 6 2239.75 3956.2 6 1982.96 4697.4 6 2437.57 .13
Transfusion requirements, mL
Packed red blood cells, mL 1040.7 6 686.94 1033.7 6 712.05 1047.6 6 669.46 .92
Fresh frozen plasma, mL 1560.2 6 687.93 1380.7 6 605.50 1739.7 6 724.83 .015
Platelets, mL 0 [0-0] 0 [0-300] .002
Temperature 34.8 6 0.93 34.7 6 1.11 34.9 6 0.74 .55
CSF, Cerebrospinal ﬂuid; LHBP, left heart bypass; SMA, superior mesenteric artery.
Data are presented at number (%), mean 6 standard deviation, and median [interquartile range].
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was performed selectively guided by the assessment of
intercostal artery back ﬂow, the quality of aortic tissue,
and the preoperative identiﬁcation of Adamkiewicz artery
based on computed tomography scans.18
The distal aortic clamp was then removed, the common
iliac arteries controlled, and the abdominal aorta opened.
Two 9F Pruitt occlusion-perfusion balloon catheters were
inserted directly into the celiac axis and superior mesenteric
artery for continued infusion of oxygenated isothermic
blood via the LHBP circuit (average ﬂow of 500 mL/
min) for TAAA extent II and III and for continued infusion
of 4C lactated Ringer’s solution for TAAA extent IV.
Two other 9F Pruitt balloon occlusion-perfusion cath-
eters were then inserted directly into the renal arteries for
continued infusion of 4C lactated Ringer’s solution or
4C Custodiol from a separate pressure line perfusion
system. The lactated Ringer’s solution for renal perfusion
was routinely supplemented with mannitol (12.5 g/L)
and methylprednisolone (125 mg/L). After rapid intra-
arterial administration of a bolus of 500 mL, cold crystalloid
was given at a perfusion pressure allowing administration of
10-20 mL/min as set at dial ﬂow. Infusion volumes larger
than 1500 mL were avoided to limit the risk of ﬂuid over-
load and systemic hypothermia as measured by nasopharyn-
geal temperature <31C. Venous venting to remove the
extra solution was never performed.
Visceral and renal arteries were managed and reat-
tached to the graft as reported in the Table IV. Mainly inthe last few years, in the case of ostial stenosis and dissec-
tion of visceral and renal arteries, intraoperative over-the-
wire dilatation using balloon-expandable stents was
preferred. This recent change in our attitude is related to
some important limitations of visceral endarterectomy,
such as the risk of vessel thrombosis (related to an unsatis-
factory end point) and perforation that may occur both
during endarterectomy and during the insertion of perfu-
sion balloon catheters in a fragile endarterectomized artery.
Often, we have also performed distal anastomosis ﬁrst,
especially using branched grafts or before the reimplanta-
tion of the left renal artery, when revascularized separately.
After repair completion and the removal of clamps and of
balloon perfusion catheters, rewarming was facilitated by
irrigating the operative ﬁeld with warm saline, warming
intravenous infusions, and activating a circulating water
mattress with heat exchanger previously placed between
the beanbag and the patient.
The clamps and cannulae of LHBP were removed, and
heparin was reverted by the infusion of protamine sulfate
to return to the baseline activated clotting time. Fenoldopam
mesylate at 0.15 mg/kg/min was routinely administered
before, during, and after aortic clamping in both groups of
patients.19 A bolus of intravenous mannitol (500 mg/kg)
and of methylprednisolone (30 mg/kg) was usually admin-
istered after induction of anesthesia. Intravenous methylene
blue was administered after unclamping. Diuretics and
inotropic agents were selectively used based on urinary
output and patient hemodynamics. In the immediate
Table V. Short-term outcomes of 84 propensity score-matched patients who underwent repair of thoracoabdominal
aortic aneurysms (TAAAs)
Total (n ¼ 84) Ringer’s group (n ¼ 42) Custodiol group (n ¼ 42) P value
Peak serum creatinine, mg/dL 2.0 6 0.95 2.1 6 0.82 1.9 6 1.07 .42
Postoperative day of peak serum creatinine, days 2.0 6 1.79 2.0 6 1.63 2.0 6 1.95 .85
Minimum peak of eGFR 40.5 6 21.61 36.2 6 17.69 44.7 6 24.41 .07
AKI
No AKI 20 (23.8) 4 (9.5) 16 (38.1) .002
AKI type 1 36 (42.9) 21 (50.0) 15 (35.7) .27
AKI type 2 13 (15.5) 9 (21.4) 4 (9.5) .13
AKI type 3 15 (17.9) 8 (19.0) 7 (16.7) .77
Renal infarction 2 (2.4) 1 (2.4) 1 (2.4) .99
Hemodialysis 2 (2.4) 0 (0) 2 (4.7) .15
CVVH 2 (2.4) 1 (2.4) 1 (2.4) .99
Hemodialysis at discharge 0 (0) 0 (0) 0 (0) .99
Transfusion requirements, No. of patients 26 (30.9) 12 (28.6) 14 (33.3) .81
Unit transfused 0 [0-1] 0 [0-1] 0 [0-1] .35
Respiratory insufﬁciency 36 (42.8) 18 (42.8) 18 (42.8) .99
Paraplegia/paraparesis 14 (16.7) 10 (23.8) 4 (9.5) .07
Ischemic bowel 3 (3.6) 2 (4.8) 1 (2.4) .55
Cerebral hemorrhage 2 (2.4) 0 (0) 2 (4.8) .15
Cardiac complication 18 (21.4) 12 (28.6) 6 (14.3) .17
Necessity for reintervention 7 (8.3) 4 (9.5) 3 (7.1) .69
Peak of LDH, mg/dL 442 [333-610] 508 [364-669] 373 [322-549] .03
Peak of CPK, mg/dL 2550 [1761-4352] 2477 [1711-4385] 2634 [1902-4269] .14
ICU time, days 2 [1-4] 3 [2-4] 1 [1-2] .0003
LOS, days 6 [5-7] 6 [4-7] 6 [6-8] .007
Operative mortality 5 (5.9) 4 (9.5) 1 (2.4) .16
In-hospital mortality 5 (5.9) 4 (9.5) 1 (2.4) .16
30-day mortality 5 (5.9) 4 (9.5) 1 (2.4) .16
AKI, Acute kidney injury; CPK, creatine phosphokinase; eGFR, estimated glomerular ﬁltration rate; ICU, intensive care unit; LDH, lactate dehydrogenase;
LOS, length of stay.
Data are presented at number (%), mean 6 standard deviation, and median [interquartile range].
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 3 Tshomba et al 627postoperative period, all patients were moved to the inten-
sive care unit for at least the ﬁrst postoperative 12 hours.
Statistical analysis. After identifying a cohort of 104
patients who had renal perfusion with Custodiol or lactated
Ringer’s solution, statistical analyses were performed using
propensity score matching to select patients for comparison
between these groups. A propensity score was generated for
each patient by performing a logistic regression using Custo-
diol perfusion as the independent variable.The followingbase-
line clinical variables, which were expected to inﬂuence renal
outcome were used for propensity scores calculation: age,
sex, hypertension, diabetes, dyslipidemia, chronic obstructive
pulmonary disease, ejection fraction, coronary artery disease,
preoperative chronic kidney disease (CKD) stage,20 and
TAAA extent. These scores were used to select two pairs of
evenly matched groups using 1 to 1 ratios for comparison.
Continuous variables were presented as mean6 standard
deviation; those with non-normal distributions were pre-
sented as median (interquartile range) whether discrete vari-
ables were reported as number (and proportion) of patients.
To compare preoperative clinical characteristics
(Table III), intraoperative surgical data (Table IV) and
postoperative outcomes, including AKI, (Table V) between
the two renal perfusion groups, two-tailed Fisher exact test,
or c2 test were used in case of categorical variables, and
two-tailed paired t-test (for normally distributed variables)or the Kruskal-Wallis test (for non-normally distributed
variables) were used in case of continuous variables. A
two-tailed P value of #.05 was considered signiﬁcant.
To compare perioperative trend (from preoperative
value up to postoperative day 6) of eGFR between the
two renal perfusion groups, a general linear model-
repeated measures analysis of variance including groups
of treatment, time, and treatment-by-time interaction in
which the within-subject variable of time (eGFR estimated
at different time points) was used.
Univariate and multivariate analyses were then per-
formed to identify possible predictors of postoperative
AKI (Table VI). In the univariate model, all preoperative,
intraoperative, and postoperative variables that were
hypothesized to have a possible effect on the development
of AKI were tested. Only variables that showed a signiﬁcant
association (P # .05) with AKI at univariate analysis were
entered in the multivariable model. For multivariate anal-
ysis, the binary logistic regression model was applied, and
the results are presented as the odds ratio with 95% conﬁ-
dence interval.
The actuarial dialysis-free survival was computed
according to the Kaplan-Meier log-rank method. In life-
table graphs, standard error exceeded 10% after 36 months
of follow-up for the Custodiol group and after 65 months
of follow-up for the lactated Ringer’s solution group.
Table VI. Univariate and multivariate analyses of acute kidney disease (AKI) predictors in the 84 propensity score-
matched patients who underwent repair of thoracoabdominal aortic aneurysm (TAAA)
Postoperative
AKI (n ¼ 64)
Nonpostoperative
AKI (n ¼ 20)
Univariate analysis Multivariate analysis
P value
OR (postoperative
AKI) P value
Age, years 67.4 6 6.03 63.4 6 12.86 .057 1.02 .63
Age, $65 years 45 (70.3) 11 (55.0) .20 - -
Sex
Male 51 (79.7) 14 (70.0) .36 - -
Dissecting aneurysm 5 (7.8) 1 (5.0) .99 - -
Diabetes mellitus 17 (26.5) 1 (5.0) .059 6.28 .14
Extracardiac arteriopathy 25 (39.1) 10 (50.0) .38 - -
Hypertension 60 (93.7) 17 (85.0) .34 - -
Smoking 59 (92.1) 19 (95.0) .99 - -
CKD
Stage 1 18 (28.1) 7 (35.0) .55 - -
Stage 2 27 (42.2) 8 (40.0) .86 - -
Stage 3 15 (23.4) 5 (25.0) .88 - -
Stage 4 4 (6.2) 0 (0) .56 - -
Stage 5 0 (0) 0 (0) .99 - -
CKD stages 3-4-5 19 (29.7) 5 (25.0) .68 - -
COPD 45 (70.3) 15 (75.0) .68 - -
Ejection fraction, % 60.0 6 6.2 58.4 6 8.1 .33 - -
Coronary artery disease 23 (35.9) 5 (25.0) .36 - -
Cerebrovascular disease 4 (6.2) 1 (5.0) .99 - -
Dyslipidemia 39 (59.4) 8 (40.0) .12 - -
Aneurysmal extent
Type 2 21 (32.8) 4 (20.0) .40 - -
Type 3 24 (37.5) 8 (40.0) .84 - -
Type 4 19 (29.7) 8 (40.0) .38 - -
Maximum aortic diameter, mm 66.0 6 15.60 64.4 6 14.14 .68 - -
ASA score 3.4 6 0.53 3.3 6 0.47 .30 - -
LHBP 46 (71.8) 13 (65.0) .55 - -
CSFD 50 (78.1) 15 (75.0) .77 - -
Ischemic times, minutes
Visceral 46.0 6 19.74 50.0 6 22.37 .45 - -
Renal 47.7 6 16.35 48.5 6 18.06 .87 - -
Isothermic 23.7 6 12.59 26.6 6 15.51 .48 - -
Cold 24.1 6 11.29 23.6 6 10.38 .85 - -
Clamping times, minutes 46.3 6 18.11 49.3 6 20.87 .53 - -
Operative repair times, minutes 276.2 6 74.82 272.6 6 56.42 .84 - -
Renal stenting 10 (15.6) 2 (10.0) .72 - -
Renal endarterectomy 8 (12.5) 1 (5.0) .34 - -
Carrel patch on visceral arteries 45 (70.3) 13 (65.0) .65 - -
Selective reimplantation of left renal artery 32 (50.0) 7 (35.0) .24 - -
Renal perfusion with Custodiol solution 26 (40.6) 16 (80.0) .004 0.17 .04
Intraoperative urinary output, mL 1345.1 6 727.40 1723.0 6 822.36 .052 1.00 .66
Intraoperative losses, mL 4402.1 6 2242.07 4085.6 6 2272.78 .58 - -
Transfusion requirements, mL
Packed red blood cells 1027.6 6 707.19 1082.5 6 633.01 .75 - -
Fresh frozen plasma 1576.9 6 683.61 1506.9 6 716.85 .75 - -
Platelets 0 [0-0] 0 [0-270] .37 - -
Peak of LDH, mg/dL 505 [359-673] 335 [291-395] <.001 0.99 .97
Peak of CPK, mg/dL 2550 [1844-4422] 2533 [1462-3323] .26 - -
ASA, American Society of Anesthesiologists; CKD, chronic kidney disease; COPD, chronic obstructive pulomonary disease; CPK, creatine phosphokinase;
CSF, cerebrospinal ﬂuid; CSFD, cerebrospinal ﬂuid drainage; LDH, lactate dehydrogenase; LHBP, left heart bypass; OR, odds ratio.
Data are presented at number (%), mean 6 standard deviation, and median [interquartile range].
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ware package (version 11.0; Stata Corporation, College
Station, Tex).
RESULTS
After propensity score adjustment, we were able to
match 42 Custodiol cases one-to-one to those receivingrenal perfusion with lactated Ringer’s solution allowing
the study to match the preset target (power analysis,
80% power with a ¼ .05) of at least 38 patients for
each group. Demographics, main comorbidities and
preoperative risk factors, TAAA Crawford’s extent, and
baseline renal function of the two groups are reported
in Table III.
Fig 1. Acute kidney injury (AKI) distribution in Custodiol and lactated Ringer’s groups.
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groups, including the use of LHBP, duration of cold and
isothermic renal distal perfusion, mean volume of infused
crystalloid solution, and urinary output (Table IV). In
the Custodiol group, longer total renal ischemic time
(51.5 6 16.48 minutes vs 43.6 6 15.99 minute; P ¼
.05), increased use of renal stenting (26.2% vs 2.4%; P ¼
.002), and increased transfusion requirements of fresh
frozen plasma (P ¼ .015) and platelets (P ¼ .002) were
observed (Table IV).
AKI occurred overall in 64 patients out of 84 (76.2%),
with a remarkable prevalence of AKI type 1 (36/84;
42.9%). Temporary hemodialysis or continuous veno-
venous hemoﬁltration were needed in 4.8% of the patients,
without any case of dialysis at discharge.
The rate of renal infarction (P ¼ .99), temporary need
for perioperative continuous veno-venous hemoﬁltration
(P ¼ .99) or hemodialysis (P ¼ .15), and hemodialysis at
discharge (P ¼ .99) in the two groups were similar
(Table V). Freedom from AKI was signiﬁcantly increased
in the Custodiol group (38.1% vs 9.5%; P ¼ .002)
(Fig 1; Table V).
Repeated measures analysis of variance showed the
main effect of time (F52,34; P < .001) and the group 
time interaction (F3,66; P < .001) to be signiﬁcant, with
an upward perioperative trend of eGFR in the Custodiol
group (Fig 2).
Age of the patient, diabetes mellitus, intraoperative
urinary output, and postoperative peak of lactate dehydro-
genase (LDH) were associated with the development of
AKI by univariate analysis, but this association was notconﬁrmed in the multivariable model (Table VI). By multi-
variate analysis (Table VI), the use of Custodiol renal
perfusion was the only independent predictor of non-AKI
(P ¼ .04).
Five patients died at 30 days (Table V), four in the
Ringer’s group and one in the Custodiol group (P ¼ .16),
and in three of them, AKI class 3 was reported. In 30-day
survivors (Ringer’s group, n ¼ 38; Custodiol group, n ¼
41), renal function at discharge returned to baseline values
in 68.3% (n ¼ 54) of the patients with a rate of permanent
postoperative renal function worsening (CKD class down-
grading) of 36.8% (n ¼ 14) in the Ringer’s group and of
26.8% (n ¼ 11) in the Custodiol group (P ¼ .4). At
a mean follow-up of 32 6 18 months (Ringer’s group,
42 6 20 months; Custodiol group, 24 6 9 months), only
one patient in the Ringer’s group developed renal failure
requiring dialysis. Calculated actuarial dialysis-free survival
at 12 and 24 months was 94.8% and 91.8% in the Custodiol
group, and 88.1% and 88.1% in the Ringer’s group, respec-
tively (log-rank, P ¼ .74; Fig 3).
DISCUSSION
Renal dysfunction is a well-known determinant of
mortality after TAAA open repair, and, despite the tech-
nical improvements of the recent decades, even the most
experienced centers still report some grade of postoperative
renal dysfunction in more than 70% of patients.3
Previous studies have demonstrated the protective
effects on renal function of hypothermia21 and of renal
artery perfusion with cold crystalloid solutions.3,4,16 Both
perfusion with isothermic and cold blood failed to support
Fig 2. Perioperative variations of estimated glomerular ﬁltration
rate (eGFR) values from preoperative value up to postoperative day
6. Comparison between the Custodiol and Ringer’s groups were
made using a general linear model-repeated measures analysis of
variance (ANOVA). Within-factor effect (time): F52,34, P < .001;
between-factor effect (group): F2,64, P ¼ .11; group  time
interaction: F3,66, P < .001.
Fig 3. Dialysis-free survival in the Custodiol and Ringer’s groups.
At key time points (0, 20, 40, and 60 months), the number of
patients in each group is listed above (log-rank test, P ¼ .74). The
grey areas indicate the standard error.
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renal protection than cold crystalloid.3,4 However, these
studies did not focus on crystalloids other than lactated
Ringer’s solution.
Custodiol is a crystalloid solution with electrolyte
concentrations similar to the intracellular environment,
containing lower levels of sodium, calcium, potassium,
and magnesium compared with lactated Ringer’s solution
(Table I). These low electrolyte concentrations should
reduce the cellular swelling, toxicity, and damage caused
by the ischemic insult.
Custodiol solution also contains high concentrations of
three main factors: (1) an amino acid buffering agent, histi-
dine/histidine hydrochloride, which provides normal
osmolarity and enhances the buffering capacity of the solu-
tion during the ischemic-induced acidosis; (2) the amino
acid tryptophan a-ketoglutarate that supports membrane
integrity; and (3) the osmotic agent mannitol. Custodiol
solution also contains a high hydrogen ion buffer level
that reduces observable acidosis associated with ongoing
anaerobic metabolism.22
The rationale for using Custodiol perfusion for renal
protection during TAAA repair derives from transplant
surgery, where the donor kidneys perfusion with the solu-
tion can maintain organ vitality during cold ischemic times
of longer than 20 hours.23 In particular, the reduced rate of
delayed graft function compared with other solutions has
been recently conﬁrmed in a meta-analysis on 3548
kidneys.22As far as the safety of the use of Custodiol in vivo is
concerned, it has been shown that even the high doses
(25 mL/kg) perfused in the heart during cardioplegia are
safe,24 although the safety threshold to be used in patients
who are not on cardiopulmonary bypass is still unknown
and warrants further investigation.
Continuous in vivo perfusion of a histidine-tryptophan-
ketoglutarate solution (Bretschneider’s solution) was
experimented in renal surgery for oncological reasons
back in 1995,25 and, apart from the temporary elevation
of serum creatinine levels, unimpaired postoperative renal
function was reported. Off-label use of Custodiol has also
been reported to protect renal function during suprarenal
aortic surgery17,26,27 and actually improved postoperative
renal function has been reported in patients who under-
went aortorenal bypass surgery.28
Unlike many studies published on these topics in
vascular surgery,3,4,16 we decided to use the Kidney
Disease Improving Global Outcomes guidelines criteria
to deﬁne end-stage renal dysfunction. This choice was
made mainly to avoid missing cases of AKI by limiting
the analysis to documented increase of serum creatinine.
We also decided to evaluate the postoperative eGFR that
is the best overall measure of kidney function both in
health and disease.29 Previous studies have described its
higher prognostic value compared with serum creatinine
alone in patients submitted to open TAAA repair.30 The
eGFR calculated using the preoperative patients’ weight
represents a surrogate measure of perioperative renal func-
tion that can be used in clinical trials.31,32 Furthermore,
our approach was methodologically consistent with
previous studies on postoperative mortality after aortic
aneurysm repair33 and coronary artery bypass grafting.34
In our study, eGFR was calculated by using the CKD-
EPI formula that required information available in our
database and had previously been used to assess the prog-
nostic value of temporary renal function decline after major
JOURNAL OF VASCULAR SURGERY
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CKD-EPI also gave the best estimation of eGFR compared
with Cockcroft-Gault and Modiﬁcation of Diet in Renal
Disease equations to a gold standard GFR measurement
using 125I-iothalamate.12
Based on these standardized criteria, our ﬁndings sup-
ported the hypothesis that Custodiol perfusion has the
potential to be more effective than lactated Ringer’s solu-
tion in preserving renal function. Our study provided statis-
tical evidence of reduction of AKI incidence in the
Custodiol group by almost two-thirds, with a reduction
of AKI rate in each AKI class, with more than one-half
the rate of AKI class II (Fig 1). Custodiol perfusion was
also associated with a signiﬁcantly improved perioperative
trend of eGFR (Fig 2). Interestingly, this signiﬁcant perio-
perative renal function improvement was reported despite
the longer total renal ischemic time and the increased
transfusion requirements reported in the Custodiol group.
Furthermore, Custodiol renal perfusion resulted as the only
independent predictor of freedom from AKI.
The possible clinical consequences of the reduction of
AKI in the early postoperative period need to be carefully
assessed, especially as AKI is often a temporary and totally
reversible postoperative complication. However, in the
Custodiol group, none of the patients presenting with
a good baseline renal function (CKD stage 1, eGFR
>90 mL/min) needed perioperative hemoﬁltration or dial-
ysis (two patients, 16.7% in the Ringer’s group). Further-
more, it was previously reported that even temporary
perioperative declines of renal function after major vascular
surgery are independent predictors for development of
long-term CKD11 and that, irrespective of its nature, AKI
is a predictor of immediate and long-term adverse
outcomes.5 It has previously been shown that there is
a near linear increase of in-hospital mortality for each
increase in AKI class; patients with AKI type I have more
than three times the mortality rate of patients without
AKI. Similarly, patients with AKI type II have close to
twice the mortality rate of AKI type I, and patients with
AKI type III have 10 times the mortality rate of hospital-
ized patients without AKI.35 In our study, the negative
prognostic value of AKI was conﬁrmed; out of ﬁve patients
who died within 30 days after surgery, four (80%) devel-
oped severe AKI and, although not statistically signiﬁcant,
the mortality rate in the group of patients with the better
renal protection was reduced (one death in the Custodiol
group, four in the Ringer’s; P ¼ .16).
Univariate analysis also showed that diabetes mellitus,
intraoperative urinary output, and postoperative peak of
LDH are associated with AKI, even if this association was
not conﬁrmed in the multivariable model. In particular,
changes in serum LDH levels have already been shown in
several acute and chronic renal diseases.36 Future studies
focused on this issue may be required to ascertain the
subtypes of isoenzymes involved to clarify their role in
AKI pathogenesis.
Study limitations. We acknowledge that the analysis
of the Ringer’s group is retrospective in nature. Theanalysis may have been biased by the several and only
partially known factors that may inﬂuence renal injury after
TAAA repair. The study groups were operated in two
different periods (although the overall period of study
was limited to only 4 years). The only way to resolve these
biases is by conducting a randomized control trial as we
planned for our further investigations to conﬁrm prelimi-
nary data of the present study.
The role of ﬂuid overload, considering the crucial role
of volume overload during AKI, the loop diuretics given,
the increased content of mannitol in the implemented
Lactated Ringer’s solution, and the role of supplementa-
tion with methylprednisolone should be carefully investi-
gated in future studies.
Finally, for the evaluation of subclinical renal injuries,
a series of speciﬁc serum and urinary biomarkers such as
RBP, a-1 microglobulin, microalbumin, N-acetyl-beta-
d-glucosaminidase, intestinal alkaline phosphatase neutrophil
gelatinase-associated lipocalin, kidney injury molecule-1,
cysteine-rich protein 61, semaphoryn 3A, urinary cystatin
C, calprotectin, urinary liver-type fatty acid-binding
protein, and urinary concentration of rennin-angiotensin
system components likely should be used in future inves-
tigations.37-40
CONCLUSIONS
The onset of AKI after TAAA open repair has a crucial
prognostic value, and any adjunct speciﬁcally addressed to
reduce its occurrence and severity should be strongly
investigated.
This study has showed that Custodiol renal perfusion is
safe and has the potential to provide better protection
against ischemic renal injury than our standard approach
with lactated Ringer’s solution. In light of these results,
at this time, we routinely use 4C Custodiol renal perfu-
sion, which is simple, effective even in prolonged times of
renal ischemia, and does not require any implementation
of the solution with osmotic agents and prednisolone as
established by our previous protocol using lactated
Ringer’s solution.
Larger series, randomized trials, use of biomarkers,
which may detect even subclinical renal injury, and evalua-
tion of other substrates are needed to conﬁrm these data
and to assess their clinical consequences.
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